ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Nerivio for Acute Treatment of Migraine in Adolescents
January 26, 2021Theranica announced its Nerivio® therapeutic device has received the U.S. Food and Drug Administration (FDA) clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. -
Nerivio Receives Expanded Indication to Cover Chronic Migraine Patients
November 02, 2020Theranica announced its Nerivio® medical device has received U.S. Food and Drug Administration (FDA) clearance for an expanded indication encompassing acute treatment of chronic migraine in people 18 years and older. -
Theranica raises $35M to bring innovative migraine device to the USA
March 19, 2019The Nerivio Migra is Investigational Device, Currently Limited by US Federal Law to Investigational Use Only in the United States
Pharma Sources Insight January 2025
